Targeted therapies in breast cancer

Seminars in Diagnostic Pathology

Volumn 25, Issue 4, 2008, Pages 245-261

  Rojo, Federico ^a,b   Albanell, Joan ^b   Rovira, Ana ^b   Corominas, Josep Maria ^b   Manzarbeitia, Felix ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Breast cancer; Estrogen receptor; FISH; HER2; Immunohistochemistry; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FLUOROURACIL; GEFITINIB; LAPATINIB; LETROZOLE; METHOTREXATE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NAVELBINE; PACLITAXEL; PERTUZUMAB; PLACEBO; PROGESTERONE RECEPTOR; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; TYCERB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADJUVANT THERAPY; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; ONCOGENE RAS; PANCREAS CANCER; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 53749084762     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.08.001     Document Type: Article

References (102)

1. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
2. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
3. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (2001) 783-792
4. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 (2002) 127-137
5. Xia W., Gerard C.M., Liu L., et al. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24 (2005) 6213-6221
6. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357 (2007) 2666-2676
7. Rojo F., Dalmases A., Corominas J.M., et al. Pharmacodynamics: biological activity of targeted therapies in clinical trials. Clin Transl Oncol 9 (2007) 634-644
8. Allred D.C., Brown P., and Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 6 (2004) 240-245
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
10. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
11. Kurosumi M. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients. Breast Cancer 10 (2003) 97-104
12. Viale G., Regan M.M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25 (2007) 3846-3852
13. Ross J.S. Improving the accuracy of hormone receptor assays in breast cancer: an unmet medical need. Future Oncol 1 (2005) 439-441
14. Goldhirsch A., Glick J.H., Gelber R.D., et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19 (2001) 3817-3827
15. Schnitt S.J. Traditional and newer pathologic factors. J Natl Cancer Inst Monogr (2001) 22-26
16. Schnitt S.J. Estrogen receptor testing of breast cancer in current clinical practice: what's the question?. J Clin Oncol 24 (2006) 1797-1799
17. Goldstein N.S., Ferkowicz M., Odish E., et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120 (2003) 86-92
18. The Consensus Conference Committee. Consensus Conference on the classification of ductal carcinoma in situ. Cancer 80 (1997) 1798-1802
19. Lebrecht A., Buchmann J., Hefler L., et al. Histological category and expression of hormone receptors in ductal carcinoma in situ of the breast. Anticancer Res 22 (2002) 1909-1911
20. Houghton J., George W.D., Cuzick J., et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362 (2003) 95-102
21. Julien J.P., Bijker N., Fentiman I.S., et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 355 (2000) 528-533
22. Wolmark N., Wieand H.S., Hyams D.M., et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92 (2000) 388-396
23. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 suppl 2 (2001) 1-13
24. Normanno N., Bianco C., De Luca A., et al. The role of EGF-related peptides in tumor growth. Front Biosci 6 (2001) D685-D707
25. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
26. Graus-Porta D., Beerli R.R., Daly J.M., et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (1997) 1647-1655
27. Pinkas-Kramarski R., Soussan L., Waterman H., et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15 (1996) 2452-2467
28. Alimandi M., Romano A., Curia M.C., et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10 (1995) 1813-1821
29. Lee A.V., Schiff R., Cui X., et al. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin Cancer Res 9 (2003) 516S-523S
30. Cortes J., Baselga J., Kellokumpu-Lehtinen P., et al. Open label, randomized, phase II study of pertuzumab in patients with metastatic breast cancer with low expression of HER2. J Clin Oncol 23 (2005) 3068
31. Baselga J., Cameron D., Miles D., et al. Objective response rate in a phase II multicenter trial of pertuzumab, a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab in patients with HER2-positive metastatic breast cancer which has progressed during treatment with T. J Clin Oncol 25 (2007) 1004
32. Albanell J., Codony J., Rovira A., et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532 (2003) 253-268
33. Arteaga C.L., and Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?. Cancer Cell 5 (2004) 525-531
34. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006) 2733-2743
35. Paik S., Hazan R., Fisher E.R., et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8 (1990) 103-112
36. Miles D.W., Harris W.H., Gillett C.E., et al. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 84 (1999) 354-359
37. Muss H.B., Thor A.D., Berry D.A., et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330 (1994) 1260-1266
38. Mano M.S., Rosa D.D., De Azambuja E., et al. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. Cancer Treat Rev 33 (2007) 64-77
39. Di Leo A., and Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?. Clin Breast Cancer 4 (2003) 179-186
40. Nielsen K.V., Ejlertsen B., Moller S., et al. The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D. Acta Oncol 47 (2008) 725-734
41. Pritchard K.I., Messersmith H., Elavathil L., et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26 (2008) 736-744
42. Perez E.A. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Breast Cancer Res Treat (2008) (in press)
43. Beser A.R., Tuzlali S., Guzey D., et al. HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res 13 (2007) 180-185
44. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354 (2006) 2103-2111
45. Konecny G.E., Thomssen C., Luck H.J., et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96 (2004) 1141-1151
46. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357 (2007) 1496-1506
47. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002) 719-726
48. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 (2005) 3676-3685
49. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
50. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
51. Carlomagno C., Perrone F., Gallo C., et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14 (1996) 2702-2708
52. Wright C., Nicholson S., Angus B., et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65 (1992) 118-121
53. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
54. Ross J.S., Fletcher J.A., Linette G.P., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8 (2003) 307-325
55. Roche P.C., Suman V.J., Jenkins R.B., et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 94 (2002) 855-857
56. Tubbs R.R., Pettay J.D., Roche P.C., et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19 (2001) 2714-2721
57. Hanna W.M., and Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol 19 (2006) 481-487
58. Tubbs R.R., Pettay J.D., Swain E., et al. Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: a feasibility study. Appl Immunohistochem Mol Morphol 14 (2006) 436-440
59. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25 (2007) 118-145
60. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 131 (2007) 18
61. Sachdev D., and Yee D. The IGF system and breast cancer. Endocr Relat Cancer 8 (2001) 197-209
62. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 5 (2000) 95-105
63. Lu Y., Zi X., Zhao Y., et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93 (2001) 1852-1857
64. Harris L.N., You F., Schnitt S.J., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13 (2007) 1198-1207
65. Liu B., Fang M., Lu Y., et al. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20 (2001) 1913-1922
66. Manders P., Beex L.V., Tjan-Heijnen V.C., et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 87 (2002) 772-778
67. Linderholm B.K., Lindahl T., Holmberg L., et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61 (2001) 2256-2260
68. Iovino F., Ferraraccio F., Orditura M., et al. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Invest 26 (2008) 250-255
69. MacConmara M., O'Hanlon D.M., Kiely M.J., et al. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. Int J Oncol 20 (2002) 717-721
70. Thielemann A., Kopczynski Z., Filas V., et al. The determination of VEGF and MVD, among patients with primary breast cancer. Pathol Oncol Res 14 (2008) 137-144
71. Schneider B.P., and Sledge Jr. G.W. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 4 (2007) 181-189
72. Quaranta M., Daniele A., Coviello M., et al. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Anticancer Res 27 (2007) 3593-3600
73. Gisterek I., Matkowski R., Kozlak J., et al. Evaluation of prognostic value of VEGF-C and VEGF-D in breast cancer: 10 years follow-up analysis. Anticancer Res 27 (2007) 2797-2802
74. Bando H., Weich H.A., Brokelmann M., et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92 (2005) 553-561
75. Mayer E.L., Lin N.U., and Burstein H.J. Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw 5 (2007) 314-323
76. Traina T.A., Rugo H.S., and Dickler M. Bevacizumab for advanced breast cancer. Hematol Oncol Clin North Am 21 (2007) 303-319
77. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
78. Herbst R.S., Heymach J.V., O'Reilly M.S., et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16 (2007) 239-249
79. Hatake K., Tokudome N., and Ito Y. Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways. Breast Cancer 14 (2007) 132-149
80. Boguski M.S., and McCormick F. Proteins regulating Ras and its relatives. Nature 366 (1993) 643-654
81. Finn R.S., Dering J., Ginther C., et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 105 (2007) 319-326
82. Johnston S.R., Hickish T., Ellis P., et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21 (2003) 2492-2499
83. Sparano J.A., Moulder S., Kazi A., et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 24 (2006) 3013-3018
84. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
85. Wang D., Boerner S.A., Winkler J.D., et al. Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773 (2007) 1248-1255
86. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 (2006) 77-82
87. Albanell J., Dalmases A., Rovira A., et al. mTOR signalling in human cancer. Clin Transl Oncol 9 (2007) 484-493
88. Lai Y.L., Mau B.L., Cheng W.H., et al. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15 (2008) 1064-1069
89. Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
90. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 (2005) 5314-5322
91. Chollet P., Abrial C., Tacca O., et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 7 (2006) 336-338
92. Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26 (2008) 1603-1610
93. Whitesell L., and Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 5 (2005) 761-772
94. Widakowich C., Dinh P., de Azambuja E., et al. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?. Anticancer Agents Med Chem 8 (2008) 488-496
95. Zsebik B., Citri A., Isola J., et al. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett 104 (2006) 146-155
96. Modi S., Stopeck A.T., Gordon M.S., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
97. Lerebours F., Vacher S., Andrieu C., et al. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8 (2008) 41
98. Singh S., Shi Q., Bailey S.T., et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 6 (2007) 1973-1982
99. Tapia M.A., Gonzalez-Navarrete I., Dalmases A., et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6 (2007) 2284-2292
100. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
101. Buyse M., Loi S., van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98 (2006) 1183-1192
102. Ioannidis J.P. Is molecular profiling ready for use in clinical decision making?. Oncologist 12 (2007) 301-311